الفهرس 
Platelet volume indices and phospholipase A2 as a potential biomarkers in acute coronary syndrome
AbstractOnly 14 pages are availabe for public view
 |  | from | 100 |  |  |
| | | from | 100 | | |
Abstract
Background: Ischemic heart disease (IHD) is the single most common cause of death worldwide. Predictive biomarkers may be helpful in diagnosis and risk stratifying IHD patients, therefore new diagnostic methods are being introduced. Aim of the work: Establishment or exclusion of the role of platelet volume indices and secretory phospholipase A2 level (PLA2) as biomarkers for screening or risk stratification in acute coronary syndrome (ACS). Subjects & Methods: We recruited 60 ACS patients presented at the Cardiology Department of Cairo University in the period from January to June 2020. Sixty normal individuals were selected in comparable strata of age and gender as the control group. Patients were subjected to: Full clinical assessment, ECG, Blood samples were collected for routine chemistry, Troponin I, Dipotassium ethylenedinitrilotetraacetic acid (EDTA) tubes for measurement of platelet indices and plain tubes for assay of sPLA2 by ELISA, Coronary angiography was performed to our study group when ACS diagnosis was established. Results: showed that there was a statistically significant difference between studied groups regarding the average PLA2 level; ACS patients had a significantly higher PLA2 level (p <0.01). At a cut-off value of {u2265} 813.5, the PLA2 yielded a sensitivity of 98.3% and specificity of 99.5% to differentiate between ACS patients and the control group. Our study demonstrated that there was a negative correlation between PLA2 and estimated glomerular filtration rate (p<0.001). We found that ACS patients had significantly higher mean platelet volume (MPV) (p<0.01) compared to the control group. At a cut-off value of {u2265} 9.05, the MPV yielded a sensitivity of 91.7% and specificity of 93.3% to differentiate between ACS patients and the control group